Aumenta le possibilità di ricevere una risposta da questo datore di lavoro
Il tuo curriculum e una lettera di presentazione personalizzati, che corrispondono esattamente a ciò che sta cercando.
The Biologics Manufacturing Centre (BMC) Inc. in Montréal, QC is seeking a Specialist, Validation, Commissioning and Qualification (CQV) for a ~12‑month maternity leave assignment.
You will plan, perform and document validation activities across facilities, utilities and CGxP equipment, ensuring regulatory compliance and data integrity. You will develop validation strategies, draft IQ/OQ/PQ protocols, execute testing and support regulatory audits, with French‑language fluency and English
The Biologics Manufacturing Centre (BMC) Inc. is a new biomanufacturing facility created in response to the pandemic. As a non-profit organization, the BMC aims to better meet the biopharmaceutical needs of Canadians. The BMC supports projects of public interest, actively contributes to the growth and overall resilience of Canada’s life sciences industry, and fosters industry development and innovation through domestic manufacturing. Driven by its engaged and innovative employees, the BMC promotes a culture of agility and transparency, with a collaborative and results-oriented approach.
We are looking for a Specialist, Validation, Commissioning and Qualification (CQV) who will play a key role in the validation of facilities, utility and computerized systems, and equipment. This person will plan, perform, and document validation activities to ensure compliance with regulatory requirements. This is a temporary assignment of approximately 12 months to cover a maternity leave.
The Specialist, Validation, Commissioning and Qualification (CQV) will have the following responsibilities:
You are the person we are looking for if:
The BMC, an employer that offers what matters to you
The BMC, an organization unlike any other
The BMC, a key player in Canadian biotechnology manufacturing
The BMC is a new facility located in the heart of Montréal, whose construction was completed in June 2021. It supports the expansion of Canada’s biologics manufacturing capacity, helping ensure that vaccines and other related products can be manufactured safely here at home. With its state-of-the-art facilities and the expertise of its team, the BMC can manufacture biopharmaceutical products such as viral-vector vaccines, protein-subunit vaccines, virus-like particle vaccines, and other biologics. It is a key contributor to Canada’s ability to respond rapidly to future national and global health emergencies.